Welcome to the Starpharma Investor CentreStarpharma Holdings Limited is an Australian stock exchange listed biotechnology company with products based on its dendrimer technology platform. |
 |
|
|
Latest News & Announcements
DEP® presentation at SNMMI radiopharmaceuticals conference (ASX Announcement)
Jun 12th, 2024
Starpharma (ASX: SPL, OTCQX: SPHRY) today provides a copy of the DEP® radiotheranostics scientific poster presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Toronto, Canada, overnight. The scientific poster presents data from Starpharma’s DEP® HER2 radiotheranostics program, demonstrating the promising utility of DEP® dendrimers in precision radiotheranostics for cancer imaging and therapeutic applications.
Read More
DEP® irinotecan presentation at ASCO 2024 Annual Meeting (ASX Announcement)
Jun 4th, 2024
Starpharma (ASX: SPL, OTCQX: SPHRY) today provides a copy of the DEP® irinotecan presentation delivered at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, US. The presentation was part of a rapid oral abstract session and highlighted the final results of the DEP® irinotecan Phase 1/2 clinical trial, which were reported in full last week.
Read More
Reports & Presentations
Click here for financial reports archive
DEP® presentation at SNMMI radiopharmaceuticals conference (ASX Announcement)
Jun 12th, 2024
Starpharma (ASX: SPL, OTCQX: SPHRY) today provides a copy of the DEP® radiotheranostics scientific poster presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Toronto, Canada, overnight. The scientific poster presents data from Starpharma’s DEP® HER2 radiotheranostics program, demonstrating the promising utility of DEP® dendrimers in precision radiotheranostics for cancer imaging and therapeutic applications.
Read More
DEP® irinotecan presentation at ASCO 2024 Annual Meeting (ASX Announcement)
Jun 4th, 2024
Starpharma (ASX: SPL, OTCQX: SPHRY) today provides a copy of the DEP® irinotecan presentation delivered at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, US. The presentation was part of a rapid oral abstract session and highlighted the final results of the DEP® irinotecan Phase 1/2 clinical trial, which were reported in full last week.
Read More